LETTER

Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis

  • Li Yang 1 ,
  • Jin Chen 1 ,
  • Jianqing Liang 1 ,
  • Yufeng Zhang 1 ,
  • Qingzhe Wang 2 ,
  • Xiaojun Ren 3 ,
  • Jinsong Wei 1 ,
  • Qianchun Gong 1 ,
  • Jiting Zhang 1 ,
  • Ning Jiang 1 ,
  • Xinhua Lin 1 ,
  • Jin Li , 1 ,
  • Bing Zhao , 1
Expand
  • 1. State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200438, China
  • 2. bioGenous Biotechnology, Inc., Hangzhou 311231, China
  • 3. Obstetrics and Gynecology Hospital of Fudan University, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai 200011, China

Accepted date: 02 Nov 2021

Published date: 15 Sep 2022

Copyright

2021 The Author(s)

Cite this article

Li Yang , Jin Chen , Jianqing Liang , Yufeng Zhang , Qingzhe Wang , Xiaojun Ren , Jinsong Wei , Qianchun Gong , Jiting Zhang , Ning Jiang , Xinhua Lin , Jin Li , Bing Zhao . Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis[J]. Protein & Cell, 2022 , 13(9) : 683 -688 . DOI: 10.1007/s13238-021-00893-0

1
Angelico R, Grimaldi C, Gazia C, Saffioti MC, Manzia TM, Castellano A, Spada M (2019) How do synchronous lung metastases influence the surgical management of children with hepatoblastoma? An update and systematic review of the literature. Cancers (basel) 11:1693

DOI

2
Driskill JH, Pan D (2021) The Hippo pathway in liver homeostasis and pathophysiology. Annu Rev Pathol 16:299–322

DOI

3
Hu H, Gehart H, Artegiani B, Lopez-Iglesias C, Dekkers F, Basak O, van Es J, de Sousa C, Lopes SM, Begthel H, Korving J et al (2018) Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell 175:1591–1606

DOI

4
O’Neill AF, Towbin AJ, Krailo MD, Xia CH, Gao Y, McCarville MB, Meyers RL, McGahren ED, Tiao GM, Dunn SP et al (2017) Characterization of pulmonary metastases in children with hepatoblastoma treated on Children’s Oncology Group protocol AHEP0731 (the treatment of children with all stages of hepatoblastoma): a report from the Children’s Oncology Group. J Clin Oncol 35:3465

DOI

5
Prior N, Hindley CJ, Rost F, Melendez E, Lau WWY, Gottgens B, Rulands S, Simons BD, Huch M (2019) Lgr5(+) stem and progenitor cells reside at the apex of a heterogeneous embryonic hepatoblast pool. Development 146:dev174557

DOI

6
Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A et al (2017) Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 65:104–121

DOI

7
Sun L, Wang Y, Cen J, Ma X, Cui L, Qiu Z, Zhang Z, Li H, Yang RZ, Wang C et al (2019) Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol 21:1015–1026

DOI

8
Sylvester KG, Colnot S (2014) Hippo/YAP, beta-catenin, and the cancer cell: a „menage a trois” in hepatoblastoma. Gastroenterology 147:562–565

DOI

9
Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S et al (2014) Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 147:690–701

DOI

10
Zhang Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF (2021) Molecular mechanisms of hepatoblastoma. Semin Liver Dis 41:28–41

DOI

11
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761

DOI

Outlines

/